The disease burden of pediatric patients with atopic dermatitis in Japan
Pediatric Dermatology · 2023-09 · 40 (5) · 851-856
DOI: 10.1111/pde.15399 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Dermatology, online erschienen am 15.08.2023. Verfasst von Yukihiro Ohya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Center, National Center for Child Health and Development, Tokyo, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Cost of Illness, Quality of Life. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi and Regeneron Pharmaceuticals, Inc..
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) is a chronic skin condition that is associated with significant patient burden and decreased health‐related quality of life (HRQoL). We report results of the real‐world Epidemiology of Children with Atopic Dermatitis Reporting on their Experience study in Japanese pediatric patients, focusing on the impact of AD severity on disease burden.
Methods
Children and adolescents aged 6 months to 17 years (or their caregivers/parents) completed an online survey between September 26, 2018, and March 5, 2019. Patients with diagnosed AD (i.e., met International Study of Asthma and Allergies in Childhood criteria and had a self‐reported AD diagnosis) were evaluated for disease severity using the Patient‐Oriented Eczema Measure (POEM). Impact of AD severity on AD symptoms (itching, pain, and sleep disturbance), disease flares, atopic comorbidities, healthcare resource utilization, school days missed, and HRQoL were assessed.
Results
Of 5702 Japanese pediatric patients, 547 had diagnosed AD and were included in this analysis. Based on POEM scores, AD severity was clear/mild in 346 patients (63.3%), moderate in 177 (32.5%), and severe in 24 (4.4%). Across all age groups (i.e., less than 6, 6–11, and 12–17 years), increased AD severity was associated with increased AD symptom severity, number of flares, atopic comorbidities, healthcare resource utilization, and school absences, as well as worsened HRQoL.
Conclusions
This population‐based study of Japanese children and adolescents showed that greater AD severity had a high impact on disease burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Allergy Center, National Center for Child Health and Development, Tokyo, Japan.
- Department of Dermatology, Nippon Medical School, Tokyo, Japan.
- Specialty Care Medical, Sanofi K.K., Tokyo, Japan.
- Market Access, Sanofi K.K., Tokyo, Japan.
- Sanofi, Cambridge, Massachusetts, USA.
- Sanofi, Chilly-Mazarin, France.
ORCID-Profile: Yukihiro Ohya, Kazuhiko Arima
Förderung
- Sanofi and Regeneron Pharmaceuticals, Inc.
Zitieren
APA
Ohya, Y., Saeki, H., Nawata, H., Arima, K., Inukai, M., Rossi, A. B., & Le-Bagousse-Bego, G. (2023). The disease burden of pediatric patients with atopic dermatitis in Japan. Pediatric Dermatology, 40(5), 851-856. https://doi.org/10.1111/pde.15399
Vancouver
Ohya Y, Saeki H, Nawata H, Arima K, Inukai M, Rossi AB, et al. The disease burden of pediatric patients with atopic dermatitis in Japan. Pediatric Dermatology. 2023;40(5):851-856. doi:10.1111/pde.15399
BibTeX
@article{Ohya2023,
author = {Ohya, Yukihiro and Saeki, Hidehisa and Nawata, Hisakatsu and Arima, Kazuhiko and Inukai, Miho and Rossi, Ana B and Le-Bagousse-Bego, Gaelle},
title = {The disease burden of pediatric patients with atopic dermatitis in Japan},
journal = {Pediatric Dermatology},
year = {2023},
volume = {40},
number = {5},
pages = {851--856},
doi = {10.1111/pde.15399}
}
EUVIMED